Immunic, Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Erik Lundgren
- Full Time Employees
- 100
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 1200 Avenue of the Americas New York City NY United States of America 10036
- IPO Date
- Apr 17, 2014
- CIK
- 0001280776
- Website
- imux.com
- Similar Companies
- Business
- Immunic, Inc. (Nasdaq: IMUX) develops a clinical-stage pipeline of orally administered small molecule therapies targeting chronic inflammatory and autoimmune diseases, including multiple sclerosis and gastrointestinal disorders; its lead product candidate, vidofludimus calcium (IMU-838), advances in phase 3 ENSURE trials for relapsing multiple sclerosis and phase 2 CALLIPER trial for progressive multiple sclerosis, demonstrating neuroprotective effects via nuclear receptor related 1 (Nurr1) activation alongside anti-inflammatory and antiviral activity through dihydroorotate dehydrogenase (DHODH) inhibition; IMU-856, a Sirtuin 6 (SIRT6) modulator, prepares for phase 2 trials in celiac disease and other gastrointestinal conditions such as inflammatory bowel disease and graft-versus-host disease; IMU-935 (izumerogant), an IL-17/RORγt inverse agonist, targets psoriasis and castration-resistant prostate cancer; and IMU-381 enters preclinical development for gastrointestinal diseases. The company, founded in 2016 as Immunic AG in Planegg-Martinsried, Germany, reorganized in April 2019 as Immunic, Inc., a Delaware corporation headquartered in New York City with its subsidiary Immunic AG in Gräfelfing near Munich conducting research and development activities; it operates primarily in the United States and Germany, serving patients with high unmet needs in neurology and gastroenterology. Recent developments include completion of enrollment in both phase 3 ENSURE trials for vidofludimus calcium in June 2025 with top-line data expected by end-2026; positive phase 2 CALLIPER results in April 2025 showing 23.8% reduction in 24-week confirmed disability worsening in progressive multiple sclerosis; long-term open-label extension data from phase 2 EMPhASIS trial in June 2025 with over 92% of relapsing-remitting multiple sclerosis patients free of disability worsening at week 144; a $65 million oversubscribed public offering in May 2025 co-led by BVF Partners and Coastlands Capital; and a $5.1 million registered direct offering led by Aberdeen Investments in April 2025.
Company News
Immunic adds new Chief People Officer ahead of Phase 3 readout
Immunic Appoints Jaa Roberson as Chief People Officer
Immunic, Inc. (NASDAQ:IMUX) Stock Has Consensus Target Price of $35.43 According to Analysts
Immunic to present four vidofludimus calcium abstracts at MSToronto2026
Immunic to Present New Clinical, Biomarker and Preclinical Data on Vidofludimus Calcium at MSToronto2026 - the 10th Joint ACTRIMS-ECTRIMS Meeting
Immunic, Inc. (IMUX) Discusses R&D Advances and Future Directions in Relapsing Multiple Sclerosis Transcript
HSBC shares carry 'sell' rating as broker says valuation leaves no room for disappointment
Palo Alto stock tumbles 10% as analysts call selloff a buying opportunity
Immunic to host virtual relapsing MS R&D Day on September 9
Immunic to Host Virtual Relapsing Multiple Sclerosis R&D Day on September 9, 2026
Immunic Appoints Chitrang Davé as Chief Data and Digital Officer
Immunic: Potent Under-The-Radar MS Lineup Set For A Rerating
Can Immunic (IMUX) Climb 163.03% to Reach the Level Wall Street Analysts Expect?
Immunic advances MS drug toward key Phase 3 data, expects results by year-end
Immunic, Inc. Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Immunic Appoints Elena Ridloff to Board of Directors
Immunic, Inc. $IMUX Shares Bought by Avidity Partners Management LP
Immunic to Participate in Investor Conferences in July
Immunic to Participate in Investor, Industry and Scientific Conferences in June
As SpaceX reportedly snips IPO valuation, prediction markets are still saying it will be a $2 trillion company